The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen

The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF). The data of 338 children were retrospectively analyzed. The patients were grouped according to joint and valve involvement and also drug chosen...

Full description

Saved in:
Bibliographic Details
Main Authors: İbrahim İlker Çetin, Murat Sürücü, Mehmet Emre Arı, Ayşe Esin Kibar, Emine Azak, Sancar Eminoğlu, Berna Şaylan Çevik, Abdullah Kocabaş, Filiz Ekici, Ali Orgun
Format: Article
Language:English
Published: Hacettepe University Institute of Child Health 2016-10-01
Series:The Turkish Journal of Pediatrics
Subjects:
Online Access:https://turkjpediatr.org/article/view/1146
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850024180761755648
author İbrahim İlker Çetin
Murat Sürücü
Mehmet Emre Arı
Ayşe Esin Kibar
Emine Azak
Sancar Eminoğlu
Berna Şaylan Çevik
Abdullah Kocabaş
Filiz Ekici
Ali Orgun
author_facet İbrahim İlker Çetin
Murat Sürücü
Mehmet Emre Arı
Ayşe Esin Kibar
Emine Azak
Sancar Eminoğlu
Berna Şaylan Çevik
Abdullah Kocabaş
Filiz Ekici
Ali Orgun
author_sort İbrahim İlker Çetin
collection DOAJ
description The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF). The data of 338 children were retrospectively analyzed. The patients were grouped according to joint and valve involvement and also drug chosen [methyl prednisolone (mPSL), ASA or NXN]. The treatment results and adverse events in each group were compared. The mean age was 10.3 years and the median follow-up was 62 months. Median time for normalization of acute phase reactants was 1 week in patients given steroids and 2 weeks in patients given ASA or NXN. ASA was replaced with NXN in 18 patients (10.2%) due to hepatic toxicity. The rate of rebound, recurrence and the prevalence of rheumatic valve disease were not different in patients given NXN, ASA or mPSL. In conclusion, NXN is a safe and effective alternative to ASA in the treatment of ARF in children.
format Article
id doaj-art-0ee467a5bdcc42618ffa04e952fd8d72
institution DOAJ
issn 0041-4301
2791-6421
language English
publishDate 2016-10-01
publisher Hacettepe University Institute of Child Health
record_format Article
series The Turkish Journal of Pediatrics
spelling doaj-art-0ee467a5bdcc42618ffa04e952fd8d722025-08-20T03:01:11ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64212016-10-0158510.24953/turkjped.2016.05.003The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxenİbrahim İlker Çetin0Murat Sürücü1Mehmet Emre Arı2Ayşe Esin Kibar3Emine Azak4Sancar Eminoğlu5Berna Şaylan Çevik6Abdullah Kocabaş7Filiz Ekici8Ali Orgun9Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey.Ankara Children's Hematology Oncology Training and Research Hospital, Pediatric Cardiology Clinic, Ankara, Turkey. The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF). The data of 338 children were retrospectively analyzed. The patients were grouped according to joint and valve involvement and also drug chosen [methyl prednisolone (mPSL), ASA or NXN]. The treatment results and adverse events in each group were compared. The mean age was 10.3 years and the median follow-up was 62 months. Median time for normalization of acute phase reactants was 1 week in patients given steroids and 2 weeks in patients given ASA or NXN. ASA was replaced with NXN in 18 patients (10.2%) due to hepatic toxicity. The rate of rebound, recurrence and the prevalence of rheumatic valve disease were not different in patients given NXN, ASA or mPSL. In conclusion, NXN is a safe and effective alternative to ASA in the treatment of ARF in children. https://turkjpediatr.org/article/view/1146acetylsalicylic acidacute rheumatic feveradverse eventsefficacynaproxen
spellingShingle İbrahim İlker Çetin
Murat Sürücü
Mehmet Emre Arı
Ayşe Esin Kibar
Emine Azak
Sancar Eminoğlu
Berna Şaylan Çevik
Abdullah Kocabaş
Filiz Ekici
Ali Orgun
The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
The Turkish Journal of Pediatrics
acetylsalicylic acid
acute rheumatic fever
adverse events
efficacy
naproxen
title The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
title_full The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
title_fullStr The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
title_full_unstemmed The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
title_short The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
title_sort efficacy and safety of naproxen in acute rheumatic fever the comparative results of 11 year experience with acetylsalicylic acid and naproxen
topic acetylsalicylic acid
acute rheumatic fever
adverse events
efficacy
naproxen
url https://turkjpediatr.org/article/view/1146
work_keys_str_mv AT ibrahimilkercetin theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT muratsurucu theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT mehmetemrearı theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT ayseesinkibar theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT emineazak theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT sancareminoglu theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT bernasaylancevik theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT abdullahkocabas theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT filizekici theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT aliorgun theefficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT ibrahimilkercetin efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT muratsurucu efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT mehmetemrearı efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT ayseesinkibar efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT emineazak efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT sancareminoglu efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT bernasaylancevik efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT abdullahkocabas efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT filizekici efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen
AT aliorgun efficacyandsafetyofnaproxeninacuterheumaticfeverthecomparativeresultsof11yearexperiencewithacetylsalicylicacidandnaproxen